

Summary of Product Characteristics

IPADINE 2% FORTE

1. NAME OF THE MEDICINAL PRODUCT:

IPADINE 2% FORTE

2. QUALITATIVE AND QUANTITATIVE COMPOSITION:

1 ml solution contains 20 mg chlorhexidine digluconate and 0.70 ml isopropanol (= isopropyl Alcohol).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM:

Dermal solution.

A clear, pink to strong pink solution, characteristic odor of isopropanol.

4. CLINICAL PARTICULARS:

4.1 Therapeutic indications:

IPADINE 2% FORTE is indicated for use in subjects aged 2 months and above for the disinfection of the skin prior to invasive medical procedures to help reduce bacteria that can potentially cause skin infection.

4.2 Posology and method of administration:

Posology: for dermal use.

IPADINE 2% FORTE may be used in subjects aged 2 months and older.

IPADINE 2% FORTE is not indicated in the paediatric population less than 2 months old (see Section 4.4 Special warnings and precautions for use).

The amount of solution to use will depend on the type of invasive medical procedure being performed and the preference of the clinician.

Avoid getting solution into hair. Wet hair is flammable. Hair may take up to 1 hour to dry.

It is recommended that the antiseptic solution remain on the skin after the procedure for continued protection. The antiseptic will gradually wear away. If early removal is desired, use alcohol. Place alcohol soaked gauze for approximately 40 seconds on the prepped area. Lightly rub gauze over area to remove the pink color.

4.3 Contraindications: Known hypersensitivity to chlorhexidine, isopropanol or any other ingredients listed in section 6.1, especially in those with a history of possible chlorhexidine related allergic reactions (see Sections 4.4 and 4.8).

4.4 Special warnings and precautions for use: For external use only on intact skin.

The solution is flammable. Do not use electrocautery procedures or other ignition sources until the skin is completely dry.

Remove any soaked materials, drapes or gowns before proceeding with the intervention. Do not use excessive quantities and do not allow the solution to pool in skin folds or under the patient or drip on sheets or other material in direct contact with the patient. Where occlusive dressings are to be applied to areas previously exposed to IPADINE 2% FORTE, care must be taken to ensure no excess product is present prior to application of the dressing.

To reduce risk of fire, apply the solution carefully:

- Avoid getting solution into hair. Wet hair is flammable. Hair may take up to 1 hour to dry.
- When prepping skin folds, toes, or fingers, use a sterile-gloved hand to hold skin apart until completely dry.
- Begin draping and/or using electrocautery only after solution is completely dry (minimum of 3 minutes on hairless skin; up to 1 hour in hair) and all wet materials are removed.

IPADINE 2% FORTE contains chlorhexidine. Rare but serious allergic reactions have been reported with products containing chlorhexidine. IPADINE 2% FORTE should not be administered to anyone with a potential history of an allergic reaction to a chlorhexidine-containing compound (see Section 4.3 and 4.8)

Keep out of eyes, ears and mouth. The solution may cause serious or permanent injury if it comes into contact with these areas. If contact occurs, rinse immediately and thoroughly with cold water and contact a doctor.

IPADINE 2% FORTE is not indicated in the age group less than 2 months old.

Do not use for lumbar puncture or in contact with the meninges. In addition, direct contact with neural tissue or the middle ear must be avoided.

Do not use on open skin wounds, broken or damaged skin or as a general skin cleaner.

Prolonged skin contact with alcohol containing solutions should be avoided. At the first sign of local skin reaction the use of IPADINE 2% FORTE should be discontinued.

4.5 Interaction with other medicinal products and other forms of interaction: The product is applied topically and the expected systemic activity is very low. No studies were performed to investigate its pharmacologic effects when used concomitantly with other medications.

4.6 Fertility, pregnancy and lactation: There are no studies with this product in pregnant or lactating women.

Pregnancy: No effects during pregnancy are anticipated since systemic exposure to chlorhexidine gluconate and isopropanol is negligible. IPADINE 2% FORTE may be used during pregnancy.

Breast-feeding: No effects on the breastfed newborn / infant are anticipated since the systemic exposure of the breast-feeding woman to chlorhexidine gluconate and isopropanol is negligible. IPADINE 2% FORTE may be used during breast-feeding.

Fertility: The effects of chlorhexidine gluconate on human reproduction have not been studied. No effects on fertility are anticipated since systemic exposure to isopropanol is negligible.

4.7 Effects on ability to drive and use machines: IPADINE 2% FORTE has no influence on the ability to drive or use machines.

4.8 Undesirable effects:

The frequency of adverse reactions is defined using the following convention:

- Very common ($\geq 1/10$)
- Common ($\geq 1/100$ to $< 1/10$)
- Uncommon ($\geq 1/1,000$ to $< 1/100$)

- Rare ($\geq 1/10,000$ to $< 1/1,000$)
- Very rare ($< 1/10,000$)
- Not known: cannot be estimated from the available data

Skin disorders:

Very rare ($< 1/10,000$): allergic or irritation skin reactions have been reported with chlorhexidine, isopropanol including erythema, rash (e.g. erythematous, papular, or maculopapular), pruritus and blisters or application site vesicles. Other local symptoms have included skin burning sensation, pain and inflammation.

Frequency unknown: dermatitis, eczema, urticaria, chemical burns in neonates.

Immune disorders:

Frequency unknown: chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock. The prevalence of chlorhexidine hypersensitivity is not known, but available literature suggests that this is likely to be rare in the perioperative setting (see Section 4.3 and 4.4).

Common: application site rash, application site erythema, application site vesicles, application site pain and application site pruritus.

Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form <https://sideeffects.health.gov.il/>

4.9 Overdose: This product is indicated for use as a preoperative surgical skin preparation and will be administered in a controlled environment by qualified personnel. In addition, the product is administered to a localised body region and is not absorbed through the skin in any significant amounts. Therefore, the potential for an overdose with this product is low.

5. PHARMACOLOGICAL PROPERTIES: Pharmacotherapeutic group: Chlorhexidine, combinations, ATC code: D08AC52.

5.1 Pharmacodynamic properties:

Mechanism of Action: Bisbiguanide antiseptics exert their lethal effect upon bacterial cells through non-specific interaction with acidic phospholipids of the cell membranes.

Chlorhexidine gluconate is a cationic biguanide. Its antimicrobial action is due to the disruption of the cell membrane and the precipitation of cell contents. It has a bactericidal or bacteriostatic action against a wide range of gram-positive and gram-negative bacteria. It is relatively ineffective against mycobacteria. It inhibits some viruses and is active against some fungi. It is inactive against bacterial spores.

Chlorhexidine gluconate has a strong binding property to skin and has a residual property on the skin. Chlorhexidine gluconate is not neutralised in the presence of organic matter.

Isopropyl alcohol is a rapidly-bactericidal and a fast-acting, broad spectrum antiseptic, but is not considered persistent. Its mechanism of action appears to be denaturation of proteins.

IPADINE 2% FORTE is a antiseptic solution containing active ingredients of 2% CHG and 70% IPA, that is effective for both rapid and persistent reduction of bacterial load across various body regions for a broad spectrum of organisms. Isopropanol (70%) provides an immediate kill of transient and resident microorganisms on the stratum corneum and 2% chlorhexidine gluconate binds to the superficial cell layers of the epidermis and provides persistent antimicrobial property that prevents regrowth of microorganisms.

Clinical studies with 2% Chlorhexidine gluconate in 70% Isopropanol have demonstrated that the combination offers equal or similar effectiveness in reducing skin bacterial load and more sustained antibacterial effects over longer periods after application, compared to the individual components alone, as well as to other commonly used antiseptics such as Povidone-iodine.

In vitro studies: IPADINE 2% FORTE meets the criteria for chemical disinfectants and antiseptic products as established by European Standards:

EN 1040 – basic bactericidal activity (Phase 1)

EN 1275 – basic yeasticidal activity (Phase 1)

IPADINE 2% FORTE meets these EN criteria for bactericidal and fungicidal activity for the following organisms at 5 minutes and 15 minutes contact time (Table 1).

Table 1: In vitro EN 1040 and EN 1275 microbiocidal effects

Strain	Contact Time	Conditions	Log Reduction	EN Criteria
<i>Pseudomonas aeruginosa</i>	5 min	100%, 75%	> 5.08	EN 1040
<i>Staphylococcus aureus</i>	5 min	100%, 75%	> 5.08	EN 1040
<i>Aspergillus brasiliensis</i>	15 min	100%, 75%	> 4.22	EN 1275
<i>Candida Albicans</i>	15 min	100%, 75%	> 4.08	EN 1275

An in vitro time-kill study was conducted using 2% Chlorhexidine gluconate in 70% Isopropanol solution products (at full strength and at 50% strength) to determine how rapidly and effectively the test products killed a variety of organisms. A total of 48 repository isolates and 144 clinical isolates were evaluated. Both the colourless and tinted formulations demonstrated >5 log₁₀ reductions at both the 3-minute and 5-minute time points for all microorganisms tested.

Another in vitro time-kill study was conducted using 2% Chlorhexidine gluconate in 70% Isopropanol solution products to determine how rapidly and effectively the test products killed a variety of organisms in the presence of a serum challenge. Six challenge microorganisms were evaluated. The tested products demonstrated >5 log₁₀ reductions at both the 3-minute and 5-minute time points for all microorganisms tested.

An in vitro antimicrobial resistance study was conducted to detect the potential for development of resistance to the test product 2% Chlorhexidine gluconate in 70% Isopropanol solution by the sequential passage of 42 clinically relevant microorganisms through increasing concentrations of the antimicrobial included in the culture media. The maximum inhibitory concentration (MIC) did not increase for any of the strains evaluated for emergence of resistance; therefore, the 2% Chlorhexidine gluconate in 70% Isopropanol solution was not considered to have the potential for the development of resistance. An evaluation of the potential for antibiotic cross-resistance was done by comparing the MIC of several antibiotics before and after extended exposure to sub-lethal levels of each antiseptic. There was no indication of a change in MIC related to cross-resistance observed for any of the organism / antibiotic combinations tested.

5.2 Pharmacokinetic properties: There is little absorption of isopropanol or of chlorhexidine gluconate through intact skin. Chlorhexidine gluconate was below the limit of detection (< 1

ng/ml) in all subjects in a clinical study designed to evaluate pharmacokinetics following dermal exposure to a maximum amount of 2% Chlorhexidine gluconate in 70% Isopropanol solution product applied to intact skin.

5.3 Preclinical safety data: Chlorhexidine gluconate and isopropanol both have long histories of safe and effective use as patient preoperative skin preparation active ingredients and a large literature database on the safety and efficacy of these two active ingredients exists. Chlorhexidine gluconate 2.0% w/v and isopropanol 70% v/v products were evaluated in a primary skin irritation study in rabbits, a murine local lymph node assay in mice, a repeated dose dermal toxicity study in rabbits, and a primary irritancy and phototoxicity in hairless mice. These studies demonstrated that there was little or no skin irritation / sensitization and with no systemic toxicity observed.

Adverse effects associated with chlorhexidine gluconate and isopropyl alcohol in non-clinical studies described in the literature were observed at systemic exposures considered sufficiently in excess of the maximum human exposure achieved by topical use, indicating little relevance to clinical use of Chlorhexidine gluconate 2.0% w/v and isopropanol 70% v/v products.

6. PHARMACEUTICAL PARTICULARS:

6.1 List of excipients: Purified Water, Carmoisine (E122 ; Azorubine).

6.2 Major incompatibilities: Chlorhexidine is incompatible with soap and other anionic agents.

6.3 Shelf life: The expiry date of the product is indicated on the bottle. Do not use after the expiry date.

Shelf life after first opening: 3 months.

6.4 Special precautions for storage: Store below 25°C in the original package to protect from light. Keep away from fire.

6.5 Nature and contents of container:

A white and turbid natural color bottle made of high-density polyethylene (HDPE) closed with a tamper evident white cap made of high-density polyethylene (HDPE).

The bottle & cap are optionally supplied with a plastic Pump. Prior use, the pump is screwed to the bottle instead of the cap.

Fill volume: 500 ml solution.

6.6 Special precautions for the disposal: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Registration Number: 167-19-36501-99

8. Manufacturer: Ben Shimon Floris Ltd., VAT no. 511126831, Industrial Park Misgav, 2017400, Israel.

9. Israeli Marketing Authorization Holder: Ben Shimon Floris Ltd., VAT no. 511126831, Industrial Park Misgav, 2017400, Israel.

Approved on: 04/2021

[IPDN-2-FRTE-DCTR-05/21 ; Last revised: 11/05/2021]